Peripheral edema is a not too uncommon finding with direct vasodilators and in most cases of treatment with these drugs does not reflect developed CHF. The authors of the original publication ...

“Philanthropic support plays a critical role in accelerating the development of these new, transformative treatments,” said ...

Despite advances in both drug and device treatment of chronic heart failure (CHF) over the last 20 years, many patients still progress to a stage of advanced CHF, characterized by increasing ...

Diabetes and heart health are closely connected. People with diabetes have a higher risk of heart failure, a condition where ...

Aldosterone is an important mediator in the pathogenesis of heart failure, and increased plasma aldosterone levels are associated with a poor prognosis. Aldosterone-receptor blocking drugs can ...

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has ...

Explore the intricate details of the Congestive Heart Failure Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Congestive Heart Failure Market ...

Advances in cardiovascular pharmacology have significantly enhanced patient outcomes through a new wave of medications ranging from anticoagulants and antiplatelet agents to lipid-lowering drugs and ...

COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure) is a confirmatory ... that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate ...